Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review

Overview

Journal JCO Oncol Pract

Specialty Oncology

Date 2022 Nov 21

PMID 36409967

Authors

Sunita Patruni

Fatima Fayyaz

Jeffrey Bien

Tony Phillip

Daniel A King

Affiliations

Soon will be listed here.

Abstract

Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human epidermal growth factor receptor 2 status, and PD-(L)1 expression on these guidelines. The role of immunotherapy in the locally advanced and metastatic setting is constantly expanding. Over the next few years, the many ongoing trials exploring immunotherapy are anticipated to bring new treatment regimens into the frontline setting with the potential to improve survival in patients with advanced disease.

Citing Articles

Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma.

Lee S, Oh H Sci Rep. 2024; 14(1):30932.

PMID: 39730741 PMC: 11680954. DOI: 10.1038/s41598-024-81764-6.

The Role of Immunotherapy in the Management of Esophageal Cancer in Patients Treated with Neoadjuvant Chemoradiation: An Analysis of the National Cancer Database.

Tasoudis P, Manaki V, Iwai Y, Buckeridge S, Khoury A, Agala C Cancers (Basel). 2024; 16(13).

PMID: 39001522 PMC: 11240428. DOI: 10.3390/cancers16132460.

Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers.

Agrawal N, Thawani R, Edmondson C, Chen E Cancers (Basel). 2023; 15(23).

PMID: 38067380 PMC: 10705178. DOI: 10.3390/cancers15235677.

The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review.

Patel N, Geropoulos G, Patel P, Bhogal R, Harrington K, Singanayagam A Cancers (Basel). 2023; 15(21).

PMID: 37958425 PMC: 10650431. DOI: 10.3390/cancers15215252.

Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.

Karim F, Amin A, Liu M, Vishnuvardhan N, Amin S, Shabbir R Cancers (Basel). 2023; 15(16).

PMID: 37627127 PMC: 10452271. DOI: 10.3390/cancers15164099.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

Sun J, Shen L, Shah M, Enzinger P, Adenis A, Doi T . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021; 398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4. View

Saeed N, Mellon E, Meredith K, Hoffe S, Shridhar R, Frakes J . Adjuvant chemotherapy and outcomes in esophageal carcinoma. J Gastrointest Oncol. 2017; 8(5):816-824. PMC: 5674263. DOI: 10.21037/jgo.2017.07.10. View

Svrcek M, Lascols O, Cohen R, Collura A, Jonchere V, Flejou J . MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Bull Cancer. 2019; 106(2):119-128. DOI: 10.1016/j.bulcan.2018.12.008. View

Kelly R, Ajani J, Kuzdzal J, Zander T, Van Cutsem E, Piessen G . Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021; 384(13):1191-1203. DOI: 10.1056/NEJMoa2032125. View

Surana R, Pant S . Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol. 2022; 1342:259-272. DOI: 10.1007/978-3-030-79308-1_8. View

Lenz H, Van Cutsem E, Limon M, Wong K, Hendlisz A, Aglietta M . First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2021; 40(2):161-170. DOI: 10.1200/JCO.21.01015. View

10.

Kang Y, Chen L, Ryu M, Oh D, Oh S, Chung H . Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind,.... Lancet Oncol. 2022; 23(2):234-247. DOI: 10.1016/S1470-2045(21)00692-6. View

11.

Fuchs C, Doi T, Jang R, Muro K, Satoh T, Machado M . Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5):e180013. PMC: 5885175. DOI: 10.1001/jamaoncol.2018.0013. View

12.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

13.

Bang Y, Van Cutsem E, Fuchs C, Ohtsu A, Tabernero J, Ilson D . KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019; 15(9):943-952. DOI: 10.2217/fon-2018-0581. View

14.

Kojima T, Shah M, Muro K, Francois E, Adenis A, Hsu C . Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020; 38(35):4138-4148. DOI: 10.1200/JCO.20.01888. View

15.

Boger C, Behrens H, Mathiak M, Kruger S, Kalthoff H, Rocken C . PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016; 7(17):24269-83. PMC: 5029700. DOI: 10.18632/oncotarget.8169. View

16.

Zhao P, Yan W, Fu H, Lin Y, Chen K . Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis. Thorac Cancer. 2018; 9(8):1048-1055. PMC: 6068451. DOI: 10.1111/1759-7714.12787. View

17.

Yeong J, Teo C, Tay R, Tan B, Chan Y, Smyth E . Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy". Gastric Cancer. 2022; 25(6):1133-1135. DOI: 10.1007/s10120-022-01343-4. View

18.

Wang X, Teng F, Kong L, Yu J . PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9:5023-39. PMC: 4990391. DOI: 10.2147/OTT.S105862. View

19.

Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K . Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. View

20.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View